INTRODUCTION
Highlyλactiveλantiretroviralλtherapyλ(HAART)λ reducesλtheλclinicalλmanifestationsλofλHIVλinj fection,λ delayingλ theλ onsetλ ofλ AIDSλ andλ subj stantiallyλimprovingλtheλprognosisλandλqualityλ ofλlifeλofλHIVjinfectedλindividuals. 1, 2 Sinceλ HAARTλ wasλ irstλ introduced,λ theλ trendλtowardsλaλreducedλmorbidityλandλmortalj ityλofλHIV/AIDSλpatientsλhasλbeenλaccompaniedλ byλtheλemergenceλofλsideλefectsλandλtoxicitiesλinλ variousλ organs. 3 λ Metabolicλ abnormalitiesλ suchλ asλ dyslipidemias,λ insulinλ resistance,λ hyperglyj cemiaλ andλ changesλ inλ bodyλ fatλ distributionλ orλ lipodystrophyλsyndromeλareλclassicλexamplesλofλ thisλsituation. 4 λSideλefectsλreducesλadherenceλtoλ treatment,λ andλ longλ termλ exposureλ toλ dyslipij demiasλinλthisλpopulationλmayλincreaseλtheλriskλ ofλcardiovascularλdiseases. 5j7 Antiretroviralλdrugsλhaveλbeenλwidelyλavailj ableλ inλ Brazil,λ sinceλ 1996λ andλ approximatelyλ 170,000λ patientsλ hadλ accessλ toλ HAARTλ unij versallyλ distributed,λ byλ theλ Brazilianλ Nationalλ HealthλSystemλ(SUS). 8 λAnalysesλofλtheλimpactλofλ HAARTλinλBrazilλhaveλshownλaλpatternλsimilarλ toλ thatλ describedλ inλ developedλ countries,λ i.e.λ aλ signiicantλ reductionλ inλ opportunisticλ diseasesλ withλ aλ consequentλ reductionλ inλ AIDSjrelatedλ hospitalizationsλandλmortality. 9 Dyslipidemiasλareλestimatedλtoλbeλfrequentλ eventsλinλpatientsλusingλHAART;λnevertheless,λ upλtoλtheλpresentλtime,λfewλstudiesλhaveλinvesj tigatedλ theλ prevalenceλ ofλ theseλ abnormalitiesλ inλ Brazil. 10j12 λ heλ presentλ studyλ aimedλ toλ estij mateλ theλ prevalenceλ ofλ dyslipidemiasλ inλ HIVj infectedλ patientsλ onλ antiretroviralλ therapy,λ inλ theλcentralλpartλofλBrazil,λandλtoλevaluateλfacj torsλassociatedλwithλtheseλabnormalities.λheseλ dataλ mayλ helpλ toλ predictλ theλ impactλ ofλ longj termλ antiretroviralλ therapyλ onλ cardiovascularλ diseasesλinλthisλgroup.
MATERIAL AND METHODS
HIVjinfectedλ patientsλ overλ 19λ yearsλ ofλ age,λ whoλ hadλ beenλ inλ useλ ofλ antiretroviralλ therapyλ forλ atλ leastλ 30λ days,λ wereλ eligibleλ toλ participateλ inλ thisλ study.λAllλofλthemλwereλregisteredλinλtheλmainλrej ferralλcenterλforλHIV/AIDSλpatients,λHospitalλforλTropicalλDisj easesλDr.λAnuarλAuadλ(HDT/AA),λinλtheλcityλofλGoiânia,λGoiás.
hisλ isλ aλ prevalenceλ studyλ withλ convenienceλ sampling.λ Sampleλ sizeλ wasλ calculatedλ toλ detectλ prevalencesλ ofλ dysj lipidemiaλ ≥λ 40%λ inλ patientsλ onλ antiretroviralλ therapyλ withλ 10%λprecision,λresultingλinλaλrequiredλsampleλofλ93λpatients.λ λ Casesλwereλidentiiedλbetweenλ2005λandλ2006.
heλ protocolλ wasλ approvedλ byλ theλ Internalλ Reviewλ Boardλ ofλtheλUniversidade Federal de Goiás.λAterλobtainingλinformedλ consent,λpatientsλwereλinterviewed,λtheirλmedicalλandλlaboratoryλ recordsλabstracted,λandλbloodλobtainedλforλlaboratoryλtesting.λPaj tientsλwithλaλhistoryλofλopportunisticλdiseaseλdiagnosedλlessλthanλ twoλmonthsλpriorλtoλtheλinterviewλwereλexcludedλfromλtheλstudy.
Aλ structuredλ interviewλ wasλ administeredλ toλ allλ parj ticipantsλ byλ theλ principalλ investigatorλ toλ collectλ social,λ dej mographicλ andλ clinicalλ data.λ Patient'sλ clinicalλ chartsλ wereλ alsoλusedλasλdataλsourcesλfromλwhichλinformationλonλduraj tionλ ofλ antiretroviralλ therapy,λ TjCD4+λ lymphocyteλ count,λ λ HIVj1λ viralλ loadλ andλ previousλ lipidλ evaluationsλ wasλ obj tained.λ Forλ theλ purposesλ ofλ analyses,λ viralλ loadλ measurej mentλ wasλ dichotomizedλ intoλ detectableλ orλ undetectable,λ andλ TjCD4+λ lymphocyteλ countλ wasλ classiiedλ asλ >λ 350λ orλ λ ≤λ350λcells/mL.λWhenλmoreλthanλoneλlaboratoryλevaluationλ wasλavailable,λtheλmostλrecentλoneλwasλused.
Followingλ theλ interview,λ theλ patientsλ wereλ referredλ forλ bloodλlipidλevaluation,λperformedλaterλanλovernightλfastingλ period.λLipidλproileλwasλobtainedλinλindividualsλwhoλwereλ metabolicallyλ stable 13 λ byλ measuringλ totalλ cholesterolλ (TC),λ highjdensityλlipoproteinλcholesterolλ(HDLjC)λandλtriglycerj idesλ(TG)λusingλanλautomatedλenzymaticλmethod.λLowjdenj sityλ lipoproteinλ cholesterolλ (LDLjC)λ wasλ calculatedλ usingλ Friedwald'sλformulaλinλindividualsλwithλtriglyceridesλ≤λ400λ mg/dL.λBloodλlipidsλwereλclassiiedλasλcategoricalλvariablesλ andλ theλ followingλ situationsλ wereλ deinedλ asλ dyslipidemia:λ TCλ≥λ240λmg/dL,λLDLjCλ≥λ160λmg/dl,λTGλ>λ200λmg/dLλand/ orλHDLjCλ<λ40λmg/dL. 13 
DISCUSSION
heλ presentλ studyλ disclosesλ aλ highλ prevalenceλ ofλ dyslipij demiaλinλpatientsλonλantiretroviralλtherapyλinλaλlargeλcityλinλ centralλBrazil.λheseλindingsλsuggestλaλpotentialλriskλforλtheλ developmentλofλcardiovascularλdiseasesλinλaλsigniicantλproj portionλofλHIV/AIDSλpatientsλinλcomingλyears.λherefore,λ theλbeneitsλobtainedλwithλtheλuseλofλHAARTλoverλtheλpastλ yearsλmayλbeλreducedλifλmeasuresλtoλminimizeλtheλnegativeλ impactλofλcardiovascularλdiseaseλinλthisλpopulationλareλnotλ implemented. heλmajorityλofλHIVjinfectedλpatientsλonλHAART,λinλourλ setting,λwereλfoundλtoλhaveλabnormalλlipidλproileλwithλpoj tentialλriskλforλcardiovascularλdiseaseλinλaλnearλfuture. 7 Patientsλusingλlipidjloweringλtherapyλwereλnotλexcludedλ fromλtheλpresentλanalysis,λand,λunexpectedly,λallλofλthemλhadλ someλ lipidλ abnormalityλ compatibleλ withλ theλ diagnosisλ ofλ dyslipidemia,λsuggestingλtheλneedλforλbetterλclinicalλcontrol,λ inλaccordanceλwithλtheλrecommendationsλguidelines. 13, 15 hereλareλwideλvariationsλinλtheλprevalenceλrateλofλdyslipj idemiaλamongλHIVjinfectedλpatientsλonλantiretroviralλtherj apy.λComparisonλofλresultsλfromλdiferentλprevalenceλstudiesλ shouldλbeλmadeλwithλcaution,λtakingλintoλconsiderationλdifj ferencesλinλmethodology,λpopulationsλstudied,λantiretroviralλ regimensλusedλbyλtheλpatients,λandλtheλcutjofλpointsλestabj lishedλtoλdeineλlipidλabnormalities.λForλtheλpurposeλofλclinij calλ management,λ theλ currentλ trendλ isλ toλ attemptλ toλ lowerλ bloodλlipidλlevels;λhence,λtheλcutjofλpointλforλtheλdefinitionλ ofλlipidλabnormalitiesλisλlower. 13 λHowever,λinλtheλpresentλ study,λ itλ wasλ decidedλ toλ applyλ moreλ conservativeλ criteriaλ withλ higherλ cutjofλ limitsλ toλ deineλ dyslipidemia,λ therebyλ guaranteeingλ greaterλ speciicityλ ofλ results.λ heλ percentageλ ofλlipidλabnormalitiesλencounteredλinλthisλstudyλwouldλhaveλ beenλevenλhigherλifλlowerλcutjofλpointsλhadλbeenλused.
Inλ ourλ sample,λ lowλ HDLλ wasλ theλ mostλ frequentλ abj normalityλ (53.7%λ ofλ patientsλ hadλ levelsλ <λ 40λ mg/dL),λ folj lowedλ byλ elevatedλ triglycerideλ levelsλ (36.1%λ ofλ patientsλ λ hadλ levelsλ >λ 200λ mg/dL).λ Approximatelyλ 40%λ ofλ patientsλ λ hadλanλelevatedλCastelliλIndexλI,λindicatingλanλincreasedλriskλ forλatheroscleroticλcardiovascularλdiseaseλinλthisλpopulation.λ hisλindexλisλconsideredλaλsimpleλapproachλforλlipidλriskλasj sessment,λtheλhighλtotalλcholesterolλisλaλmarkerλforλatheroj genicλlipoproteinsλandλlowλHDLλcholesterolλcorrelatesλwithλ riskλfactorsλofλmetabolicλsyndrome. 14, 16 Fewλ studiesλ onλ theλ prevalenceλ ofλ dyslipidemiaλ carriedλ outλ inλ Brazilλ haveλ beenλ published. 10j12 λ Inλ theλ northeastλ rej gion,λaλcrossjsectionalλstudy 12 λconductedλamongλaλsampleλofλ 372λpatientsλwithλandλwithoutλantiretroviralλtherapyλfoundλ highλTC,λlowλHDLλandλhighλTGλlevelsλinλ20.1%,λ57.1%λandλ 26.5%λ ofλ subjects,λ respectively.λ Aλ studyλ conductedλ inλ theλ southeast 11 λinvolvingλ238λpatients,λpredominantlyλusingλPI,λ foundλlowλHDLλinλ65%λofλparticipantsλandλhypertriglycerij demiaλ inλ 46%λ ofλ them,λ usingλ diferentλ cutjofλ pointsλ fromλ thoseλusedλinλourλstudy.λ Diferentλ antiretroviralλ drugsλ mayλ beλ associatedλ withλ abnormalitiesλ inλ lipidλ proile.λ Variousλ studiesλ haveλ shownλ anλassociationλbetweenλtheλuseλofλPIλandλdyslipidemia. 5, 7, 12 λ heλprevalenceλandλdegreeλofλlipidλabnormalities,λhowever,λ varyλbetweenλtheλdiferentλdrugs,λwithinλaλsingleλclassλandλ possiblyλwithλdurationλofλtreatment. 17 λheλpresentλstudyλwasλ notλ designedλ toλ evaluateλ diferencesλ betweenλ drugsλ withinλ theλsameλclass.λheλuseλofλPIλwasλassociatedλwithλtheλpresj enceλofλdyslipidemiaλevenλaterλsimultaneousλadjustmentλforλ possibleλconfoundingλfactorsλsuchλasλsex,λageλandλtimeλsinceλ λ diagnosisλofλHIV/AIDS.λheλdurationλofλPIλuseλwasλnotλinj cludedλinλtheλlogisticλregressionλmodel.λNevertheless,λthereλ wasλnoλevidenceλofλanyλcorrelationλbetweenλdurationλofλPIλ useλ andλ serumλ HDLjCλ levelsλ (pλ =λ 0.12).λ Contraryλ toλ ourλ indings,λanotherλstudyλconductedλinλBrazil 11 λreportedλaλcorj relationλbetweenλdurationλofλPIλuseλandλHDLjCλlevels.
Theλ associationλ betweenλ NNRTIλ useλ andλ dyslipij demiasλ isλ controversial.λ Aλ growingλ numberλ ofλ reportsλ suggestλ thatλ useλ ofλ thisλ classλ ofλ drugsλ mayλ leadλ toλ anλ increaseλinλlipids. 17, 18 λInλagreementλwithλourλresults,λanj otherλ studyλ conductedλ inλ London 19 λ foundλ noλ increaseλ inλ totalλ cholesterolλ orλ inλ triglyceridesλ inλ patientsλ onλ NNRTI.λ Otherλ investigatorsλ haveλ reportedλ anλ increaseλ inλHDLjCλinλpatientsλonλthisλclassλofλdrugs,λwhichλmayλ haveλaλprotectiveλeffectλagainstλtheλdevelopmentλofλcoroj naryλdisease. 20 Oneλofλtheλlimitationsλofλtheλpresentλstudyλisλnotλhavj ingλincludedλtheλcumulativeλhistoryλofλtheλpriorλuseλofλ antiretrovirals.λItλisλpossibleλthatλpatientsλonλPI,λmainlyλ thoseλonλritonavirjboostedλregimens,λmayλhaveλhadλtheλ diseaseλ forλ aλ longerλ timeλ andλ mayλ haveλ beenλ exposedλ toλvariousλdrugsλpreviously,λwhichλmayλhaveλinterferedλ inλ theirλ currentλ lipidλ profile.λ Toλ minimizeλ thisλ effect,λ anλ estimationλ ofλ theλ timeλ ofλ HIVλ infection/AIDSλ wasλ includedλ inλ theλ logisticλ regressionλ modelλ asλ surrogateλ markerλforλtheλtimeλofλuseλofλantiretroviralλdrugs.
Someλ otherλ methodologicalλ issuesλ withλ respectλ toλ theλsiteλatλwhichλcasesλwereλrecruitedλandλtheλsamplingλ processλshouldλalsoλbeλmentioned.λPatientsλregisteredλatλ theλprincipalλreferralλserviceλforλHIV/AIDSλinλtheλstateλ ofλGoiásλwereλrecruitedλtoλthisλstudy.λThisλreferralλcenterλ isλresponsibleλforλtheλnotificationλofλalmostλallλcasesλofλ AIDSλinλtheλstate.λ Despiteλ48.1%λofλtheseλpatientsλhadλaλdetectableλviralλ loadλweλcannotλconcludeλthatλtheyλwereλinappropriatelyλ treated.λViralλloadλassessmentλisλusedλtoλmonitorλtherj apyλandλaroundλhalfλtheseλpatientsλunderwentλaλchangeλ inλ theirλ antiretroviralλ regimenλ followingλ evaluationλ ofλ plasmaλviremia.
Assumingλthatλtheλsampleλofλpatientsλstudiedλisλrepj resentative,λ ourλ resultsλ indicateλ aλ highλ prevalenceλ ofλ dyslipidemiaλandλriskλforλtheλdevelopmentλofλcardiovasj cularλdiseaseλinλaλsignificantλproportionλofλpatientsλwithλ HIV/AIDSλinλtheλyearsλtoλcomeλinλcentralλpartλofλBrazil.λ Furthermore,λasλmostλofλpatientsλunawareλofλtheirλlipidλ abnormalities,λtheλfindingsλofλthisλstudyλunderscoreλtheλ needλtoλadoptλstrategiesλtoλroutinelyλevaluateλandλmodij fyλtheλriskλofλcardiovascularλdiseasesλinλthisλpopulation.
